Nosocomial outbreak of OXA-18-producing Pseudomonas aeruginosa in Tunisia

Clinical Microbiology and Infection

Volumn 13, Issue 8, 2007, Pages 794-800

  Kalai Blagui, S ^a   Achour, W ^a   Abbassi, M S ^a   Bejaoui, M ^a   Abdeladhim, A ^b   Ben Hassen, Assia ^a  

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^b PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Ceftazidime resistance; Extended spectrum lactamase; Nosocomial outbreak; OXA 18; PCR; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE OXA 18; BETA LACTAMASE TEM 1; CEFEPIME; CEFTAZIDIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION; ENZYME INHIBITION; ENZYME SYNTHESIS; EPIDEMIC; GENOTYPE; HEALTH CARE FACILITY; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; ISOELECTRIC FOCUSING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; SEQUENCE ANALYSIS; TUNISIA;

PSEUDOMONAS AERUGINOSA;

EID: 34447293757     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01757.x     Document Type: Article

References (43)

1. Weldhagen GF, Poirel L, Nordmann P. Ambler Class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: Novel developments and clinical impact. Antimicrob Agents Chemother 2003; 47: 2385-2392.
2. Philippon LN, Naas T, Bouthors AT et.al. OXA-18, a class D clavulanic acid-inhibited extended spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2188-2195.
3. Philippon A. Pseudomonas aeruginosa: Phénotype de résistance aux antibiotiques. Med Mal Infect 1998; 28: 134-149.
4. Ambler RF. The structure of β-lactamases. Philos Trans R Soc Lond (Biol) 1980; 289: 321-331.
5. Poirel L, Ronco E, Naas T et al. Extended spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. Clin Microbiol Infect 1999; 5: 651-652.
6. Dubois V, Arpin C, Noury P et.al. Clinical strain of Pseudomonas aeruginosa carrying a bla TEM-21 gene located on a chromosomal interrupted TnA type transposon. Antimicrob Agents Chemother 2002; 46: 3624-3626.
7. Mugnier P, Dubrous P, Casin I et.al. A TEM-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 2488-2493.
8. Marchandin H, Jean-Pierre H, De Champs C et.al. Production of a TEM-24 plasmid-mediated extended-spectrum β-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 213-216.
9. Naas T, Philippon LN, Poirel L et al. An SHV-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1281-1284.
10. Chanawong A, M'Zali HF, Heritage J et al. SHV-12, SHV-5, SHV-2a and VEB-1 extended spectrum β-lactamase in gram negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother 2001; 48: 839-852.
11. Ben-Hamouda T, Foulon T, Ben Mehrez K. Involvement of SHV-12 and SHV-2a encoding plasmids in outbreak of extended-spectum β-lactamase-producing Klebsiella pneumoniae in Tunisia neonatal ward. Microb Drug Resist 2004; 10: 132-138.
12. Poirel L, Brinas L, Verlinde A et.al. BEL-1, a novel clavulanic acid-inhibited extended-spectrum β-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3743-3748.
13. Danel F, Hall LMC, Gur D et.al. OXA-15, an extended-spectrum variant of OXA-2 β-lactamase isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 1997; 41: 785-790.
14. Poirel L, Gerome P, De Champs C et.al. Integron-located OXA-32 gene cassette encoding an extended-spectrum variant of OXA-2 β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 566-569.
15. Hall LMC, Livermore D, Gur D et.al. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 1644-1649.
16. Danel F, Hall LMC, Gur D et.al. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1881-1884.
17. Danel F, Hall LMC, Gur D et.al. OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase from two Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 1998; 42: 3117-3122.
18. Danel F, Hall LMC, Duke B et.al. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1362-1366.
19. Mugnier P, Casin I, Bouthors AT et.al. Novel OXA-10 derived extended-spetrum β-lactamase selected in vivo or in vitro. Antimicrob Agents Chemother 1998; 42: 3113-3116.
20. Poirel L, Girlich D, Naas T et.al. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid and integron located gene. Antimicrob Agents Chemother 2001; 45: 447-453.
21. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharmaceut Des 1999; 5: 865-879.
22. Jarlier V, Nicolas NH, Fournier G et.al. Extended broad spectrum-β-lactamase conferring transferable resistance to newer β-lactams in enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
23. De Champs C, Poirel L, Bonnet R et.al. Prospective survey of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002; 46: 3031-3034.
24. Barthélémy M, Peduzzi J, Ben-Yaghlane H et.al. Single amino acid substitution between SHV-1 β-lactamase and cefotaxime-hydrolysing SHV-2 enzyme. FEBS Lett 1988; 231: 217-220.
25. Anthony M, Rose B, Pegler BM et.al. Genetic analysis of Pseudomonas aeruginosa isolated from the sputa of Australian adult cystic fibrosis patients. J Clin Microbiol 2002; 40: 2772-2778.
26. Costa PFLP, Teixeira LM, Carvalho MGS et.al. Occurrence of a multidrug-resistant Pseudomonas aeruginosa clone in different hospitals in Rio de Janeiro, Brazil. J Clin Microbiol 2002; 40: 2420-2424.
27. Kalai S, Achour W, Abdeladhim A et.al. Pseudomonas aeruginosa isolés de patients immunodeprimés: Résistance aux antibiotiques, sérotypage et typage moléculaire. Méd Mal Infect 2005; 35: 530-535.
28. Struelens MJ, Schwam V, Deplano A et.al. Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients. J Clin Microbiol 1993; 31: 2320-2326.
29. Clark NC, Cooksey RC, Hill BC et.al. Characterisation of glycopeptide-resistant enterococci from US hospitals. Antimicrob Agents Chemother 1993; 37: 2311-2317.
30. Rasheed JK, Gay C, Metchock B et.al. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41: 647-653.
31. Bert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother 2002; 50: 11-18.
32. Macrina FL, Kopecko DJ, Jones KR et.al. A multiple plasmid-containing Escherichia coli strain: Convenient source of size reference plasmid molecules. Plasmid 1978; 1: 417-420.
33. Kado CL, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol 1981; 145: 1365-1373.
34. Livermore DM, Jones CS. Characterisation of NPS-1, a novel plasmid-mediated β-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 1986; 29: 99-103.
35. Coetzee JN, Datta N, Hedges NW. R factors from Proteus rettgeri. J Gen Microbiol 1973; 72: 543-552.
36. Cavallo JD, Leblanc F, Fabre R et.al. Surveillance de la sensibilitéde Pseudomonas aeruginosa aux antibiotiques en France et distribution des mécanismes de résistance aux β-lactamines: Étude GERPB 1999. Pathol Biol 2001; 49: 1-6.
37. Girlich D, Naas T, Leelaporn A et.al. Nosocomial spread of the integron-located VEB-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clin Infect Dis 2002; 34: 603-611.
38. Kolayli F, Gacar G, Karadenizli A et.al. PER-1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett 2005; 249: 241-245.
39. Bert F, Ould Houcine Z, Juvin M et.al. Evaluation of the Osiris Expert system for identification of β-lactam phenotypes isolates in Pseudomonas aeruginosa. J Clin Microbiol 2003; 41: 3712-3718.
40. Bou Kaddida J, De Montalember M, Gaillard JL et.al. Outbreak of colonisation by Pseudomonas aeruginosa in immunocompromised children undergoing total digestive decontamination: Analysis by pulsed-field electrophoresis. J Clin Microbiol 1991; 29: 2069-2071.
41. Thomson KS. Controversies about extended-spectrum and AmpC β-lactamases. Emerg Infect Dis 2001; 7: 333-336.
42. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1999; 8: 557-584.
43. Sabiha YE, Hall LMC, Devadas GP et.al. Complexity and diversity of K. pneumoniae strains with extended-spectrum β-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob Agents Chemother 2001; 45: 88-95.